Last reviewed · How we verify
PRX-100
At a glance
| Generic name | PRX-100 |
|---|---|
| Sponsor | LENZ Therapeutics, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia (PHASE2)
- Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRX-100 CI brief — competitive landscape report
- PRX-100 updates RSS · CI watch RSS
- LENZ Therapeutics, Inc portfolio CI